Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer

Last updated: March 31, 2025
Sponsor: Galderma R&D
Overall Status: Completed

Phase

3

Condition

Squamous Cell Carcinoma

Sun Poisoning

Skin Cancer

Treatment

Photodynamic therapy with Metvix 160 mg/g cream

Clinical Study ID

NCT00472459
PC T313/03
  • Ages > 18
  • All Genders

Study Summary

Participants on immunosuppressive therapy, e.g., organ recipients, had higher occurrence of AK (Actinic Keratosis) than the untreated population. Keratotic lesions (i.e., AK lesions and warts) in this population were highly associated with development of SCC (Squamous Cell Carcinoma) also with 10 times higher mortality rate because of SCC than expected. The risk of developing skin cancer, predominantly SCC and BCC (Basal Cell Carcinoma), increased with graft survival time and the length of immunosuppressive treatment period.

The higher risk of developing skin malignancy and more aggressive skin malignancies in this population, indicated the need for early removal of these pre-malignant lesions.

In this study, two contralateral areas (5x10 cm^2) with skin lesions within the participant were compared. One area was received Metvix PDT at defined intervals and the other was received lesion specific treatment at the discretion of the investigator. The primary endpoint was the accumulated number of new lesions during the study and number of AK lesions that showed complete response 3 months after baseline. Secondary endpoints were number of BCC lesions that showed complete response, number of recurrent lesions, assessment of cosmetic outcome and safety.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Transplant recipients with at least 2 clinically diagnosed AK lesion and maximum 10skin lesions (AK, BCC, SCC in situ and/or warts) in each of the two contralateralareas (diameter 5x10^2 cm) in the face, the scalp, the extremities or on thetrunk/neck.

  • Transplant recipients who previously were treated more than once for their skinlesions.

  • Transplant recipients who had received immunosuppressive therapy for more than 3years.

  • Males or females above 18 years of age.

  • Written informed consent.

Exclusion

Exclusion Criteria:

  • Participants with more than 10 skin lesions (AK, BCC, SCC in situ, warts) in one ofthe two areas.

  • Participants with SCC (not SCC in situ) in one of the two areas.

  • Participants not previously treated or treated only once for their skin lesions.

  • Participants with rosacea in one of the two areas.

  • Participants with morphea form/highly infiltrating BCC

  • Known allergy to methyl-amino levulinate, a similar compound or excipients of thecream

  • Participation in other clinical studies either concurrently or within the last 30days.

  • Pregnant or breast-feeding (all women of child-bearing potential documented anegative pregnancy test and used the pill or IUD during the treatments and for atleast one month thereafter).

  • Conditions associated with a risk of poor protocol compliance

Study Design

Total Participants: 82
Treatment Group(s): 1
Primary Treatment: Photodynamic therapy with Metvix 160 mg/g cream
Phase: 3
Study Start date:
July 25, 2003
Estimated Completion Date:
July 14, 2006

Study Description

The treatment area (5x10 cm^2) was treated at baseline and at 3 ,9 and 15 months visits. At baseline, the area was treated with fractionated Metvix® PDT treatment consisting of two treatment one week apart and at 3 ,9 and 15 months visits with single Metvix® PDT treatment. The participants were evaluated for occurrence of new lesions, lesion response and recurrence at 3 (not recurrence),9,15,21, and 27 months visits. New and recurrent lesions in the treated area were treated with Metvix® PDT treatment. Lesions with partial response in the treated area were re-treated with Metvix® PDT and lesions with no response were treated with lesion specific treatment at the discretion of the investigator.

In the contralateral control area (5x10 cm^2), new and recurrent lesions and lesions in non-complete response were treated with lesion specific treatment at the discretion of the investigator at each study visit.

Connect with a study center

  • Department of Dermatolgy, Roskilde Amtsygehus

    Roskilde, 4000
    Denmark

    Site Not Available

  • Department of Dermatology, Roskilde Amysygehus

    Roskilde, 4000
    Denmark

    Site Not Available

  • Department of Dermatology, Ã…rhus Amysygehus

    Ã…rhus, 8000
    Denmark

    Site Not Available

  • Department of Dermatology, Århus Amysygehus

    Århus, 8000
    Denmark

    Site Not Available

  • Klinik für Dermatologie, Venerologie und Allergologie, Campus Charité Mitte

    Berlin, 10117
    Germany

    Site Not Available

  • Hautklinik Linden

    Hannover, 30449
    Germany

    Site Not Available

  • Department of Dermatology, Rikshospitalet

    Oslo, 0027
    Norway

    Site Not Available

  • Department of Dermatology, St. Olavs Hospital

    Trondheim, 7006
    Norway

    Site Not Available

  • Department of Dermatology, Sahlgrenska University Hospital

    Gothenburg, 41345
    Sweden

    Site Not Available

  • Department of Dermatology, Karolinska University Hospital, Huddinge

    Stockholm, 14186
    Sweden

    Site Not Available

  • Department of Dermatology, Uppsala University Hospital

    Uppsala, 75185
    Sweden

    Site Not Available

  • Dermatology Department, Manchester Royal Infirmary

    Manchester, M13 9WL
    United Kingdom

    Site Not Available

  • Portsmouth Dermatology Centre, St Mary's Hospital

    Portsmouth, PO3 6AD
    United Kingdom

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.